The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | M | Musculo-skeletal system | |
2 | M04 | Antigout preparations | |
3 | M04A | Antigout preparations |
Active Ingredient | Description | |
---|---|---|
Allopurinol |
Allopurinol is a xanthine-oxidase inhibitor. Allopurinol and its main metabolite oxipurinol lower the level of uric acid in plasma and urine by inhibition of xanthine oxidase, the enzyme catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid. |
|
Benzbromarone |
|
|
Colchicine |
Colchicine is considered to act against the inflammatory response to urate crystals, by possibly inhibiting the migration of granulocytes into the inflamed area. Other properties of colchicine, such as interaction with the microtubules, could also contribute to the operation. Onset of action is approximately 12 hours after oral administration and is maximal after 1 to 2 days. |
|
Febuxostat |
Uric acid is the end product of purine metabolism in humans and is generated in the cascade of hypoxanthine → xanthine → uric acid. Both steps in the above transformations are catalyzed by xanthine oxidase (XO). Febuxostat is a 2-arylthiazole derivative that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting XO. |
|
Lesinurad |
Lesinurad is a selective uric acid reabsorption inhibitor that inhibits uric acid transporter URAT1. URAT1 is responsible for the majority of the reabsorption of filtered uric acid from the renal tubular lumen. By inhibiting URAT1, lesinurad increases uric acid excretion and thereby lowers serum uric acid (sUA). Lesinurad also inhibits OAT4, a uric acid transporter involved in diuretic-induced hyperuricaemia. |
|
Pegloticase |
Pegloticase is a uric acid specific enzyme which is a recombinant uricase and achieves its therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid. Allantoin is an inert and water soluble purine metabolite; it is readily eliminated, primarily by renal excretion. |
|
Probenecid |
Probenecid is a uricosuric and renal tubular blocking agent. It inhibits the tubular reabsorption of urate, thus increasing the urinary excretion of uric acid and decreasing serum urate levels. Effective uricosuria reduces the miscible urate pool, retards urate deposition, and promotes resorption of urate deposits. |
|
Topiroxostat |
|
Title | Information Source | Document Type | |
---|---|---|---|
ADENURIC Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
COLCHICINA | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
COLCHICINE Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
KRYSTEXXA Solution for infusion | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
PROBENECID-AFT Film coated tablet | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
ULORIC Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
ZYLOPRIM Tablet | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
ZYLORIC Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |